Ness Ziona, Israel and Bangkok, Thailand (PRWEB) November 23, 2005 -
TheraVitae, producer of VesCell™ - adult stem cell therapy for heart disease, will present the latest advances in its ongoing research into blood-borne stem cell biology and its clinical applications at the 47th Annual Meeting of the American Society of Hematology. Both oral and poster presentations will showcase the new stem cell population TheraVitae scientists have isolated from human blood. The ability to obtain this population directly from blood using a simple, painless and rapid isolation process constitutes a major breakthrough in adult stem cell research. Building on the clinical success that VesCell has already demonstrated in the treatment of severe heart disease, this new stem cell population is the scientific cornerstone of TheraVitae’s strategy to expand into commercial treatments for additional disorders such as peripheral artery disease in the near future.
"These exciting scientific developments place TheraVitae one step further ahead of its competitors in stem cell research", said Dr. Yael Porat, Senior Director of R&D, "We are pushing the boundaries of stem cell science by constantly developing new cellular products with therapeutic potential. Thanks to the hard work of our dedicated R&D staff, we are moving ever closer to being able to treat a wide variety of diseases with adult stem cells."
Dr. Valentin Fulga, CEO of Theravitae, added: "Bringing these results to the scientific community, especially at a prestigious meeting such as the American Society of Hematology annual meeting, is fundamental to TheraVitae's strategy of advancing scientific research into adult stem cells and their clinical applications. We intend to remain a pioneer in the development of innovative cell-based treatments that will offer new hope to patients suffering from diseases that are presently considered to be incurable. We are proud to have had this wonderful opportunity to present our achievements in stem cell research to the broad, professional audience they deserve."
VesCell™ uses a patient’s own adult stem cells to treat Heart Disease and is a viable alternative for patients who either cannot undergo or choose not to undergo the standard treatment such as Coronary Artery Bypass Grafting (CABG).
VesCell™ uses adult stem cells harvested from approximately ½ pint of the patients own blood to treat several heart conditions. Once harvested, the cells are differentiated and expanded in vitro at TheraVitae’s Labs in Israel. They are ready for implantation in about one week.
TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, and Hong Kong.
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel